设为首页  |   加入收藏        
文章摘要
Qidongxu.Efficacy and Safety of Iguratimod and Methotrexate in Treatment of Active Rheumatoid Arthritis[J].中国药物评价,2019,36(3):217-220
甲氨蝶呤与艾拉莫德治疗类风湿关节炎的 有效性及安全性研究
Efficacy and Safety of Iguratimod and Methotrexate in Treatment of Active Rheumatoid Arthritis
投稿时间:2018-10-31  修订日期:2019-05-20
DOI:
中文关键词: 艾拉莫德  甲氨蝶呤  类风湿关节炎  有效性  安全性
英文关键词: Iguratimod  Methotrexate  Rheumatoid arthritis  Efficacy  Safety
基金项目:
作者单位E-mail
齐东旭 吉林省一汽总医院 48936707@qq.com 
刘颖 吉林省一汽总医院  
黄东辉 吉林省中医药科学院第一临床医院  
摘要点击次数: 95
全文下载次数: 0
中文摘要:
      目的:研究艾拉莫德(IGU)与甲氨蝶呤(MTX)治疗类风湿关节炎(RA)的有效性及安全性。方法:对我院就诊的活动期RA患者120例,随机分为3组,MTX组、IGU组、MTX+IGU组,每组各40例。治疗24 w后进行疗效及安全性评估。结果:治疗后,MTX组ACR20(20%美国风湿病学会标准改善率)有19例(47.5%),IGU组ACR20有20例(50.0%),MTX+IGU组ACR20有29例(72.5%),MTX+IGU组明显优于单药治疗组,3组比较有统计学意义(P<0.05)。治疗后DAS28(完全缓解率)比较无统计学差异,MTX+IGU组DAS28比例最高(27.5%),高于MTX组(12.5%)及IGU组(15.0%)。比较ACR标准各个项目均有所好转,且IGU与MTX疗效相当,MTX+IGU优于单药治疗,3组比较有统计学意义。不同治疗组不良反应发生率无显著性差异。结论:本研究显示IGU、MTX治疗活动期RA的疗效及安全性无显著差异,MTX+IGU治疗优于单药治疗且具有良好的安全性,可为临床用药提供参考。
英文摘要:
      Objective:This study aimed to investigate the efficacy and safety of rheumatoid monotherapy combined with methotrexate in the treatment of rheumatoid arthritis. Methods: 120 patients with active rheumatoid arthritis (RA) were divided into three groups: methotrexate group (MTX) (n=40), Iguratimod group (IGU) (n=40), and methotrexate plus Iguratimod group (MTX plus IGU) (n=40). The course of treatment was 24 weeks, and the efficacy and safety were evaluated at 24 weeks. Results: After 24 weeks of treatment, there were 19 cases (47.5%) of ACR20 in MTX group, 20 cases (50.0%) in IGU group, and 29 cases (72.5%) in IGU plus MTX group. The efficacy and safety of MTX plus IGU were significantly superior to that of a single use of IGU or MTX (P<0.05). There was no significant difference in the EULALR remission rate (DAS28 remission) between groups after 24 weeks of treatment (MTX plus IGU: 27.5% vs. MTX: 12.5% vs. IGU: 15.0%, P>0.05). All items in ACR criteria at 24 weeks have been improved compared with that at 0 weeks. Moreover, a significant difference was observed between groups in the improvement of items in ACR criteria. Among that, MTX plus IGU was superior to a single use of IGU or MTX, while no difference between IGU and MTX. There was no significant difference in the incidence of adverse reactions between groups. Conclusion: There is no significant difference in the efficacy and safety between iguratimod and methotrexate in the treatment of active rheumatoid arthritis. A combination of Iguratimod with methotrexate provides better efficacy and safety compared with a single use of Iguratimod or methotrexate.
查看全文   查看/发表评论  下载PDF阅读器
关闭
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=8C69D9BCA894EB9071080FB3B333F5C57DE78FB8C92562E0B4DA9EFEAD11D21E08A4E0A5EF00368352084288864FAD395A58102269CE684351965E8ED7180315D8F6F989685E8C96F6F95A7A53F603D17789F29E9141735B8CACF37F72253128&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=C67D2F8D2B6D9BA9&jid=7E2D005B9876DF2C49428C8EADF4A462&yid=B6351343F4791CA3&aid=&vid=&iid=38B194292C032A66&sid=F9F74EC1AA08A7B9&eid=1D67BE204FBF4800&fileno=2018199&flag=1&is_more=0">